We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Groundbreaking Blood Test Offers Early Pancreatic Cancer Diagnosis

By LabMedica International staff writers
Posted on 04 Mar 2024

Pancreatic cancer ranks as the third leading cause of cancer-related deaths, primarily due to its late detection. More...

Early discovery of the disease, while it's still treatable, could significantly impact survival rates. For more than a century, scientists have sought to link cancer with cellular energy production and metabolism. The advent of quantitative mass spectrometry has enabled the testing of many such theories. Now, for the first time, researchers have utilized targeted mass spectrometry to demonstrate that pancreatic cancer stems from changes in cellular metabolism that are detectable using a simple blood test. This method could lead to more precise and earlier diagnoses of pancreatic cancer than currently possible with tumor markers or imaging techniques, potentially paving the way for more timely and appropriate therapeutic interventions.

In contrast to genomic approaches that measure DNA for early detection and often struggle with false positives and negatives, mass spectrometry can measure extremely low concentrations of biochemicals in plasma with remarkable accuracy. Scientists at Metabolomycs (Long Beach, CA, USA) have found that these metabolic signatures in the blood can predict survival rates in patients battling this aggressive cancer. This discovery marks a new direction in pancreatic cancer research, moving beyond genomics and DNA analysis to define the disease as a metabolic disorder.

According to the researchers, variations in amino acids, blood sugars, and lipids define cancer as a state of metabolic stress. Metabolomics, a novel scientific field, employs sensitive tools like mass spectrometry to quantify metabolic byproducts in blood and other bodily fluids. Although mass spectrometry has broad applications, the emergence of targeted mass spectrometry has facilitated its direct clinical use. For the first time, researchers can accurately measure blood levels of metabolic byproducts in real-time. This enabled the researchers to discover highly discriminating ratios that pitted amino acids, the building blocks of proteins, against lipids including triglycerides and sugars like glucose. These findings provide a unique "cancer signature" that differentiates individuals with pancreatic cancer from healthy subjects and can also distinguish pancreatic cancer from other cancer types, such as breast and ovarian cancer.

"What we find is that pancreatic cancers establish a new set of rules for making and using energy that propel these malignant tumors to succeed, all at the expense of the cancer patient's wellbeing," said Dr. Robert Nagourney. "Our findings show that these metabolic tests have the potential to identify pancreatic cancers at the earliest stages when it is still possible to cure the patient. They can also be used to define risk groups that help predict a patient's likelihood of survival."

Related Links:
Metabolomycs


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.